• Home
  • Search Results
  • eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion.

eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion.

The Journal of investigative dermatology (2015-01-07)
Shahram Khosravi, Kevin J Tam, Gholamreza S Ardekani, Magdalena Martinka, Kevin J McElwee, Christopher J Ong

Human cutaneous melanoma is a devastating skin cancer because of its invasive nature and high metastatic potential. We used tissue microarray to study the role of human eukaryotic translation initiation factor 4E (eIF4E) in melanoma progression in 448 melanocytic lesions and found that high eIF4E expression was significantly increased in primary melanomas compared with dysplastic nevi (P<0.001), and further increased in metastatic melanomas (P<0.001). High eIF4E expression was associated with melanoma thickness (P=0.046), and poor overall and disease-specific 5-year survival of all, and primary melanoma patients, especially those with tumors ≥1 mm thick. Multivariate Cox regression analysis revealed that eIF4E is an independent prognostic marker. eIF4E knockdown (KD) in melanoma cells resulted in a significant increase in apoptosis (sub-G1 populations) and decrease in cell proliferation, and also resulted in downregulation of mesenchymal markers and upregulation of E-cadherin. In addition, eIF4E KD led to a decrease in melanoma cell invasion, matrix metalloproteinase-2 expression and activity, c-myc and BCL2 expression, and an increase in cleaved PARP and cleaved caspase-3 expression and chemosensitivity. Taken together, our data suggest that the eIF4E may promote melanoma cell invasion and metastasis, and may also serve as a promising prognostic marker and a potential therapeutic target for melanoma.

Product Number
Product Description

Trimesic acid, 95%
Trimethylaluminum, 97%
Trimethylaluminum solution, 2.0 M in toluene
Trimethylaluminum, packaged for use in deposition systems
Trimethylaluminum solution, 2.0 M in hexanes
Trimethylaluminum solution, 2.0 M in heptane

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.